The aim of the Core is to provide support and enhance the progress, productivity, cost-effectiveness, and outcome of the three research projects. The research projects focus on human and mouse genetic approaches to uncover genes for non-syndromic conotruncal heart defects (CTDs). All of the projects will utilize the Core, as it will have a fundamental role in administrating the Program. The Core will also help in human subject recruitment. It will recruit new 22q11 DS subjects and their parents for expanding the CNV landscape and to provide a replication of the GWAS, as proposed in Project 1. In addition, investigators in the Core, will oversee evolving clinical phenotyping. Specifically, Project 3 depends on an up to date understanding of the 22q11 DS phenotype and how it relates to non-syndromic malformations. The """"""""phenotyping center"""""""" for which the Core in part serves, will provide essential intellectual guidance in areas of clinical human genetics. Finally, the core will make decisions as to which research site will carry out genomic assays including Affymetrix 6.0 arrays (Project 1), genotyping (Projects 1 and 2), sequence capture and next generation sequencing (NGS;Projects 1 and 2). The Core will negotiate best pricing and services when they are needed. The core will also organize travel for the Pi's for semimonthly meetings and travel to the NICHD Structural Birth Defects meeting in Washington DC.
Relevance: The program to discover genes for cardiac outflow development and disease will help to develop future therapeutics for treatment. The goal of the core is to help recruit human subjects with the 22q11.2 deletion and to support Projects 1, 2 and 3 administratively.
|Johnston, Jennifer J; van der Smagt, Jasper J; Rosenfeld, Jill A et al. (2018) Autosomal recessive Noonan syndrome associated with biallelic LZTR1 variants. Genet Med 20:1175-1185|
|Zhao, Yingjie; Guo, Tingwei; Fiksinski, Ania et al. (2018) Variance of IQ is partially dependent on deletion type among 1,427 22q11.2 deletion syndrome subjects. Am J Med Genet A 176:2172-2181|
|Morrow, Bernice E; McDonald-McGinn, Donna M; Emanuel, Beverly S et al. (2018) Molecular genetics of 22q11.2 deletion syndrome. Am J Med Genet A 176:2070-2081|
|Guo, Tingwei; Diacou, Alexander; Nomaru, Hiroko et al. (2018) Deletion size analysis of 1680 22q11.2DS subjects identifies a new recombination hotspot on chromosome 22q11.2. Hum Mol Genet 27:1150-1163|
|Grand, Katheryn; Levitt Katz, Lorraine E; Crowley, T Blaine et al. (2018) The impact of hypocalcemia on full scale IQ in patients with 22q11.2 deletion syndrome. Am J Med Genet A 176:2167-2171|
|Hasten, Erica; McDonald-McGinn, Donna M; Crowley, Terrence B et al. (2018) Dysregulation of TBX1 dosage in the anterior heart field results in congenital heart disease resembling the 22q11.2 duplication syndrome. Hum Mol Genet 27:1847-1857|
|Gur, R E; Bassett, A S; McDonald-McGinn, D M et al. (2017) A neurogenetic model for the study of schizophrenia spectrum disorders: the International 22q11.2 Deletion Syndrome Brain Behavior Consortium. Mol Psychiatry 22:1664-1672|
|Agopian, A J; Goldmuntz, Elizabeth; Hakonarson, Hakon et al. (2017) Genome-Wide Association Studies and Meta-Analyses for Congenital Heart Defects. Circ Cardiovasc Genet 10:e001449|
|Johnston, H Richard; Chopra, Pankaj; Wingo, Thomas S et al. (2017) PEMapper and PECaller provide a simplified approach to whole-genome sequencing. Proc Natl Acad Sci U S A 114:E1923-E1932|
|Hoang, Thanh T; Marengo, Lisa K; Mitchell, Laura E et al. (2017) Original Findings and Updated Meta-Analysis for the Association Between Maternal Diabetes and Risk for Congenital Heart Disease Phenotypes. Am J Epidemiol 186:118-128|
Showing the most recent 10 out of 44 publications